Pacritinib

Pacritinib is a prescription medication used to treat myelofibrosis, a type of cancer of the bone marrow. It is a kinase inhibitor, meaning it works by blocking certain proteins that can cause the abnormal growth of cells in the bone marrow. Pacritinib is used in combination with other medications to reduce certain symptoms associated with myelofibrosis, including enlarged spleen and anemia.

Pacritinib is a medication used to treat a specific type of bone marrow cancer called myelofibrosis (MF) in adults [1, 2]. Here's a closer look at what Pacritinib is and how it works:

What is Myelofibrosis?

• Myelofibrosis is a rare disorder where scar tissue builds up in the bone marrow, affecting its ability to produce healthy blood cells [1].
• This can lead to symptoms like fatigue, weakness, enlarged spleen, and easy bleeding [3].

How Does Pacritinib Work?

• Pacritinib belongs to a class of drugs called kinase inhibitors.
• It works by blocking the activity of abnormal proteins (JAK2, FLT3, IRAK1) that signal cancer cells to multiply in myelofibrosis [2, 4].
• By inhibiting these proteins, Pacritinib can help slow down the growth and spread of cancer cells and improve some symptoms of myelofibrosis.

Who Can Take Pacritinib?

• Pacritinib is specifically indicated for adults with intermediate- or high-risk primary or secondary myelofibrosis with a low platelet count (less than 50 x 10⁹/L) [1].
• It's not suitable for everyone with myelofibrosis, and other treatment options might be considered depending on the specific case.

How is Pacritinib Given?

• Pacritinib is taken orally (by mouth) as a capsule, typically twice daily with or without food [1].

Important Considerations:

• Pacritinib can cause side effects, including diarrhea, fatigue, nausea, and increased risk of infections [1].
• It can also interact with other medications, so it's crucial to inform your doctor about all medications you take before starting Pacritinib [5].
• Pacritinib is a relatively new medication, and long-term effects are still under investigation [3].